Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 5/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504155 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A | |
| SCHEMBL504098 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A | |
| SCHEMBL504218 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A | |
| SCHEMBL505083 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A | |
| SCHEMBL505084 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A | |
| SCHEMBL504217 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A | |
| SCHEMBL504099 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A | |
| SCHEMBL14122305 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A | |
| SCHEMBL504296 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A | |
| SCHEMBL505066 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HSD17B10IMPDH2NAMPTMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) | 2012-02-02 | — | — | US | claimed |
| EP-2394649-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-12-14 | — | — | EP | claimed |
| EP-1411984-B1 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES WHICH CONTAINS CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | LEO PHARMA AS (DK) | 2008-05-07 | — | — | EP | claimed |
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) | 2012-02-02 | — | — | US | disclosed |
| EP-2394649-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-12-14 | — | — | EP | disclosed |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | PLPBP, PYGL, QDPR | ALDH1A1 4182/4885HSD17B10 3843/4885IMPDH2 1033/4885 |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | IKBKE, IKBKG, IKBKB | ALDH1A1 3943/4885HSD17B10 2928/4885IMPDH2 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.